Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NIPENT vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Purine nucleoside analog that inhibits DNA synthesis and repair by incorporating into DNA and inhibiting ribonucleotide reductase and DNA polymerases.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Hairy cell leukemia,Cutaneous T-cell lymphoma
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
5 mg/m2 intravenously over 20-30 minutes every 3 weeks.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Terminal elimination half-life is approximately 5-8 hours in patients with normal renal function. Clinically, the half-life may be prolonged in renal impairment, requiring dose adjustments.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Primarily metabolized by the liver via deamination by adenosine deaminase (ADA).
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Primarily renal excretion; approximately 50-70% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination accounts for <5%.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Approximately 90-95% bound to serum albumin.
82–88% bound to plasma proteins (primarily albumin).
Volume of distribution (Vd) is approximately 0.4 L/kg, indicating distribution primarily into extracellular fluid.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Not applicable; Nipent is only administered intravenously with 100% bioavailability via that route. Oral bioavailability is negligible and not clinically relevant.
Oral: 65–80% (median 73%)
Contraindicated if creatinine clearance < 60 m L/min. For Cl Cr 60-90 m L/min: reduce dose to 2.5 mg/m2. Not recommended if Cl Cr < 60 m L/min.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
No specific dose adjustment guidelines for Child-Pugh class A or B. Use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Safety and efficacy not established in pediatric patients <18 years. No recommended weight-based dosing.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
No specific dose adjustments recommended for elderly based on age alone; monitor renal function closely as older patients are more likely to have decreased creatinine clearance.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
WARNING: NIPENT (pentostatin) can cause severe bone marrow suppression, leading to neutropenia, thrombocytopenia, and anemia. Fatal hemorrhagic events and infections have occurred. Use with caution in patients with impaired renal function.
None
Bone marrow suppression: monitor blood counts regularly,Renal toxicity: assess renal function before and during therapy,Hepatotoxicity: monitor liver function tests,Pulmonary toxicity: observe for signs of pneumonitis,Embryofetal toxicity: advise patients of reproductive potential to use effective contraception,Increased risk of infection: avoid live vaccines
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Hypersensitivity to pentostatin or any component of the formulation,Severe hepatic impairment,Pregnancy (risk of fetal harm)
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
Grapefruit and grapefruit juice should be avoided due to potential CYP3A4 inhibition. No other significant food interactions are reported.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
Pregnancy Category D. First trimester: potential teratogenicity (based on animal studies and limited human data). Second and third trimesters: risk of fetal harm (e.g., myelosuppression, growth restriction).
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
Contraindicated during breastfeeding. M/P ratio unknown; pentostatin is excreted in human milk with potential for serious adverse reactions in nursing infants.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
No established safe dose; avoid use in pregnancy. If unavoidable, consider reduced dosing based on increased volume of distribution and renal clearance, but individualize with close monitoring for toxicity.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
Administer with aggressive pre-hydration (≥2L NS) and urine alkalinization to prevent nephrotoxicity. Monitor for severe myelosuppression, especially neutropenia. Consider leukapheresis for high-risk patients to prevent tumor lysis syndrome. Dose adjustment required for renal impairment (Cr Cl <60 m L/min).
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Drink at least 2-3 liters of water daily to protect kidneys.,Report any unusual bleeding, bruising, or signs of infection (fever, sore throat) immediately.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception during and for 6 months after therapy.,Do not receive live vaccines during treatment.,Report any new or worsening shortness of breath or chest pain.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NIPENT vs AGRYLIN, answered by our medical review team.
NIPENT is a Antineoplastic Agent that works by Purine nucleoside analog that inhibits DNA synthesis and repair by incorporating into DNA and inhibiting ribonucleotide reductase and DNA polymerases.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NIPENT and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NIPENT is: 5 mg/m2 intravenously over 20-30 minutes every 3 weeks.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NIPENT and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NIPENT is classified as Category C. Pregnancy Category D. First trimester: potential teratogenicity (based on animal studies and limited human data). Second and third trimesters: risk of fetal harm (e.g., myelosuppre. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.